Cel-Sci Corporation (NYSEAMERICAN:CVM) announced its quarterly earnings results on March 12, 2024, revealing a loss of ($0.68) earnings per share (EPS) for the quarter, as reported by FiscalAI. Following the announcement, the company’s stock experienced a decline of 2.4%, trading down $0.12 to reach $4.78 per share. A total of 15,956 shares changed hands, significantly lower than the average trading volume of 69,211 shares.
With a market capitalization of $40.20 million, Cel-Sci’s price-to-earnings ratio stands at -0.49 and its beta at 0.77. The company’s stock has fluctuated between a 12-month low of $1.98 and a 12-month high of $20.41. Financial indicators show a current ratio of 2.26, a quick ratio of 2.20, and a debt-to-equity ratio of 0.36. The fifty-day and two-hundred-day simple moving averages are currently $5.43 and $7.52, respectively.
Institutional Trading Activity
Recent trading activity indicates that several institutional investors have adjusted their positions in Cel-Sci. Notably, State Street Corp increased its holdings by 9.9% during the fourth quarter, now owning 25,570 shares valued at approximately $134,000 after adding 2,300 shares. Similarly, Jane Street Group LLC acquired a new stake worth around $83,000 during the same period.
Other significant transactions include HRT Financial LP, which purchased shares valued at about $60,000, and Renaissance Technologies LLC, which also acquired a new position worth approximately $81,000. Additionally, Geode Capital Management LLC expanded its holdings by 30.3%, owning 79,183 shares valued at $417,000 after acquiring an additional 18,432 shares. Overall, institutional investors now hold 12.08% of Cel-Sci’s stock.
Company Overview
Founded in 1983 and headquartered in Vienna, Virginia, Cel-Sci Corporation is a biotechnology company focused on developing immunotherapy products aimed at treating cancer and infectious diseases. The company utilizes its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® platforms to enhance the body’s immune response against various diseases.
Cel-Sci operates as a clinical-stage organization, translating immunological insights into therapeutic candidates. Its lead product, Multikine (leukineferon), is an investigational immunotherapy designed to bolster the immune system’s ability to target head and neck cancer cells.
As the company continues its efforts in the biotechnology sector, stakeholders will be closely observing its progress and upcoming developments.
